• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析和腹膜透析患者肠道微生物组组成的结构和功能差异。

Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Division of Transplantation Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.

出版信息

Sci Rep. 2017 Nov 15;7(1):15601. doi: 10.1038/s41598-017-15650-9.

DOI:10.1038/s41598-017-15650-9
PMID:29142271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5688134/
Abstract

Complications of end-stage renal disease (ESRD) are critically related to inflammation. The gut microbiome is a key driver of inflammation. Since dialysis modalities may differently influence the gut microbiome, we aimed to compare the effects of haemodialysis (HD) and peritoneal dialysis (PD) on patients' gut microbiome composition and function. We therefore studied faecal microbiome composition and function as well as inflammation and gut permeability in 30 patients with ESRD (15 HD, 15 PD) and compared to 21 healthy controls. We found an increase in potentially pathogenic species and a decrease in beneficial species in patients on HD and to a lesser extend in patients on PD when compared to controls. These changes in taxonomic composition also resulted in differences in predicted metagenome functions of the faecal microbiome. In HD but not in PD, changes in microbiome composition were associated with an increase in c-reactive protein (CRP) but not with intestinal inflammation or gut permeability. In conclusion microbiome composition in ESRD differs from healthy controls but also between modes of dialysis. These differences are associated with systemic inflammation and cannot completely be explained by dialysis vintage. The mode of renal replacement therapy seems to be an important driver of dysbiosis in ESRD.

摘要

终末期肾病(ESRD)的并发症与炎症密切相关。肠道微生物组是炎症的关键驱动因素。由于透析方式可能会对肠道微生物组产生不同的影响,我们旨在比较血液透析(HD)和腹膜透析(PD)对患者肠道微生物组组成和功能的影响。因此,我们研究了 30 名 ESRD 患者(15 名 HD,15 名 PD)的粪便微生物组组成和功能以及炎症和肠道通透性,并与 21 名健康对照进行了比较。与对照组相比,我们发现 HD 组和 PD 组中潜在致病物种的数量增加,有益物种的数量减少。这种分类组成的变化也导致了粪便微生物组预测宏基因组功能的差异。在 HD 组中,但不是在 PD 组中,微生物组组成的变化与 C 反应蛋白(CRP)的增加有关,但与肠道炎症或肠道通透性无关。总之,ESRD 患者的微生物组组成与健康对照组不同,而且在不同的透析模式之间也不同。这些差异与全身炎症有关,不能完全用透析时间来解释。肾脏替代治疗的方式似乎是 ESRD 中菌群失调的一个重要驱动因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/2c271001b578/41598_2017_15650_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/8a1601e6a0b7/41598_2017_15650_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/6d7985ae2b6d/41598_2017_15650_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/bb2617c9d01f/41598_2017_15650_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/d8a78b23cb22/41598_2017_15650_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/fd60ea276b03/41598_2017_15650_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/2c271001b578/41598_2017_15650_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/8a1601e6a0b7/41598_2017_15650_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/6d7985ae2b6d/41598_2017_15650_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/bb2617c9d01f/41598_2017_15650_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/d8a78b23cb22/41598_2017_15650_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/fd60ea276b03/41598_2017_15650_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/5688134/2c271001b578/41598_2017_15650_Fig6_HTML.jpg

相似文献

1
Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.血液透析和腹膜透析患者肠道微生物组组成的结构和功能差异。
Sci Rep. 2017 Nov 15;7(1):15601. doi: 10.1038/s41598-017-15650-9.
2
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study.儿科终末期肾病患者的肠道微生物群:中西部儿科肾脏病联盟的研究。
Microbiome. 2016 Sep 17;4(1):50. doi: 10.1186/s40168-016-0195-9.
3
Peritoneal dialysis promotes microbial-driven biosynthesis pathways of sesquiterpenes and triterpenes compounds in end-stage renal disease patients.腹膜透析促进终末期肾病患者中微生物驱动的倍半萜和三萜化合物的生物合成途径。
BMC Microbiol. 2024 Sep 28;24(1):377. doi: 10.1186/s12866-024-03539-3.
4
The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses.血液透析和腹膜透析对终末期肾病患者肠道微生物群的影响以及肠道微生物群与患者预后的关系。
Front Cell Infect Microbiol. 2021 Mar 23;11:579386. doi: 10.3389/fcimb.2021.579386. eCollection 2021.
5
High-throughput sequencing analysis of intestinal flora changes in ESRD and CKD patients.高通量测序分析终末期肾病和慢性肾脏病患者肠道菌群变化。
BMC Nephrol. 2020 Jan 13;21(1):12. doi: 10.1186/s12882-019-1668-4.
6
Correlation between gut microbiome and cognitive impairment in patients undergoing peritoneal dialysis.肠道微生物组与腹膜透析患者认知障碍的相关性。
BMC Nephrol. 2023 Dec 5;24(1):360. doi: 10.1186/s12882-023-03410-z.
7
Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial.晚期糖基化终产物饮食限制对腹膜透析患者肠道细菌微生物群的影响;一项随机开放标签对照试验。
PLoS One. 2017 Sep 20;12(9):e0184789. doi: 10.1371/journal.pone.0184789. eCollection 2017.
8
Urgent-Start Peritoneal Dialysis and Hemodialysis in ESRD Patients: Complications and Outcomes.终末期肾病患者的紧急起始腹膜透析和血液透析:并发症与结局
PLoS One. 2016 Nov 8;11(11):e0166181. doi: 10.1371/journal.pone.0166181. eCollection 2016.
9
Dialysis-related systemic microinflammation is associated with specific genomic patterns.透析相关的全身微炎症与特定的基因组模式相关。
Nephrol Dial Transplant. 2008 May;23(5):1673-81. doi: 10.1093/ndt/gfm804. Epub 2007 Nov 29.
10
Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study.菊粉型果聚糖干预可限制腹膜透析患者肠道微生物群产生的吲哚增加:一项随机交叉研究。
Am J Clin Nutr. 2020 May 1;111(5):1087-1099. doi: 10.1093/ajcn/nqz337.

引用本文的文献

1
Peritoneal Dialysis -Associated Fibrosis: Emerging Mechanisms and Therapeutic Opportunities.腹膜透析相关性纤维化:新出现的机制与治疗机会
Front Pharmacol. 2025 Aug 22;16:1635624. doi: 10.3389/fphar.2025.1635624. eCollection 2025.
2
Absorbents therapy, as a conservative option, can improve kidney function in chronic kidney disease.吸附剂疗法作为一种保守治疗方法,可改善慢性肾脏病患者的肾功能。
Arch Razi Inst. 2024 Aug 1;79(4):695-700. doi: 10.32592/ARI.2024.79.4.695. eCollection 2024 Aug.
3
Gut microbiota and kidney function in autosomal dominant polycystic kidney disease participants in Cameroon: a cross-sectional study.

本文引用的文献

1
Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.肾功能受损和肠道微生物群落失调导致慢性肾脏病患者中三甲胺-N-氧化物水平升高。
Sci Rep. 2017 May 3;7(1):1445. doi: 10.1038/s41598-017-01387-y.
2
Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.基于 CE-TOFMS 的代谢组学方法评价肠道微生物群对尿毒症溶质积累的影响。
Kidney Int. 2017 Sep;92(3):634-645. doi: 10.1016/j.kint.2017.02.011. Epub 2017 Apr 8.
3
Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.
喀麦隆常染色体显性多囊肾病患者的肠道微生物群与肾功能:一项横断面研究。
BMC Nephrol. 2025 Jan 13;26(1):20. doi: 10.1186/s12882-025-03942-6.
4
Probiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials.益生菌干预在腹膜透析中的应用:潜在机制与治疗潜力综述
World J Nephrol. 2024 Dec 25;13(4):98719. doi: 10.5527/wjn.v13.i4.98719.
5
Peritoneal dialysis promotes microbial-driven biosynthesis pathways of sesquiterpenes and triterpenes compounds in end-stage renal disease patients.腹膜透析促进终末期肾病患者中微生物驱动的倍半萜和三萜化合物的生物合成途径。
BMC Microbiol. 2024 Sep 28;24(1):377. doi: 10.1186/s12866-024-03539-3.
6
Gut Microbiota in Patients Receiving Dialysis: A Review.接受透析患者的肠道微生物群:综述
Pathogens. 2024 Sep 15;13(9):801. doi: 10.3390/pathogens13090801.
7
Impact of mechanical bowel preparation on the gut microbiome of patients undergoing left-sided colorectal cancer surgery: randomized clinical trial.左半结肠癌手术患者机械肠道准备对肠道微生物组的影响:随机临床试验。
Br J Surg. 2024 Aug 30;111(9). doi: 10.1093/bjs/znae213.
8
Uncovering specific taxonomic and functional alteration of gut microbiota in chronic kidney disease through 16S rRNA data.通过 16S rRNA 数据揭示慢性肾脏病中肠道微生物群落的特定分类和功能改变。
Front Cell Infect Microbiol. 2024 Apr 19;14:1363276. doi: 10.3389/fcimb.2024.1363276. eCollection 2024.
9
Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.肠道微生物群与慢性肾衰竭之间的因果关系:一项两样本孟德尔随机化研究。
Front Microbiol. 2024 Apr 3;15:1356478. doi: 10.3389/fmicb.2024.1356478. eCollection 2024.
10
Analysis of intestinal flora and cognitive function in maintenance hemodialysis patients using combined 16S ribosome DNA and shotgun metagenome sequencing.采用 16S 核糖体 DNA 和鸟枪法宏基因组测序分析维持性血液透析患者的肠道菌群和认知功能。
Aging Clin Exp Res. 2024 Feb 9;36(1):28. doi: 10.1007/s40520-023-02645-y.
2型糖尿病和慢性肾脏病中的肠道微生物群
Curr Diab Rep. 2017 Mar;17(3):16. doi: 10.1007/s11892-017-0841-z.
4
Plasma Zonulin and its Association with Kidney Function, Severity of Heart Failure, and Metabolic Inflammation.血浆连蛋白及其与肾功能、心力衰竭严重程度和代谢性炎症的关系。
Clin Lab. 2016 Dec 1;62(12):2443-2447. doi: 10.7754/Clin.Lab.2016.160512.
5
Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases.闭合蛋白,一种上皮和内皮屏障功能的调节因子,及其在慢性炎症性疾病中的作用。
Tissue Barriers. 2016 Oct 21;4(4):e1251384. doi: 10.1080/21688370.2016.1251384. eCollection 2016.
6
Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, D-lactate and markers of inflammation in haemodialysis patients.血液透析患者血浆中zonulin、细菌脂多糖、D-乳酸水平与炎症标志物之间的关系
Int Urol Nephrol. 2017 Apr;49(4):717-725. doi: 10.1007/s11255-016-1495-5. Epub 2017 Jan 2.
7
Mode of renal replacement therapy determines endotoxemia and neutrophil dysfunction in chronic kidney disease.肾脏替代治疗方式决定慢性肾脏病患者的内毒素血症和中性粒细胞功能障碍。
Sci Rep. 2016 Oct 4;6:34534. doi: 10.1038/srep34534.
8
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study.儿科终末期肾病患者的肠道微生物群:中西部儿科肾脏病联盟的研究。
Microbiome. 2016 Sep 17;4(1):50. doi: 10.1186/s40168-016-0195-9.
9
Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality.在晚期慢性肾脏病中,感染会导致心血管事件、终末期肾病和死亡的风险增加。
Kidney Int. 2016 Oct;90(4):897-904. doi: 10.1016/j.kint.2016.07.013. Epub 2016 Aug 31.
10
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk.健康泰国素食者和非素食者的微生物群落、其核心肠道微生物群以及病原体风险
J Microbiol Biotechnol. 2016 Oct 28;26(10):1723-1735. doi: 10.4014/jmb.1603.03057.